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Abstract
Background: After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete
response (pCR) rates are being achieved especially in patients with squamous cell carcinoma (SCC). An active
surveillance strategy has been proposed for SCC patients with clinically complete response (cCR) after nCRT. To justify
omitting surgical resection, patients with residual disease should be accurately identified. The aim of this study is to
assess the accuracy of response evaluations after nCRT based on the preSANO trial, including positron emission
tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic
ultrasonography (EUS) with fine-needle aspiration (FNA) in patients with potentially curable esophageal SCC.
Methods: Operable esophageal SCC patients who are planned to undergo nCRT according to the CROSS regimen and
are planned to undergo surgery will be recruited from four Asian centers. Four to 6 weeks after completion of nCRT,
patients will undergo a first clinical response evaluation (CRE-1) consisting of endoscopy with bite-on-bite biopsies. In
patients without histological evidence of residual tumor (i.e. without positive biopsies), surgery will be postponed
another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10–12 weeks after completion of
nCRT, consisting of PET-CT, endoscopy with bite-on-bite biopsies and EUS with FNA. Immediately after CRE-2 all
patients without evidence of distant metastases will undergo esophagectomy. Results of CRE-1 and CRE-2 as well as
results of the three single diagnostic modalities will be correlated to pathological response in the resection specimen
(gold standard) for calculation of sensitivity, specificity, negative predictive value and positive predictive value.
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Discussion: If the current study shows that major locoregional residual disease (> 10% residual carcinoma or any
residual nodal disease) can be accurately (i.e. with sensitivity of 80.5%) detected in patients with esophageal SCC, a
prospective trial will be conducted comparing active surveillance with standard esophagectomy in patients with a
clinically complete response after nCRT (SINO trial).
Trial registration: The preSINO trial has been registered at ClinicalTrials.gov as NCT03937362 (May 3, 2019).
Keywords: Esophageal cancer, Squamous cell carcinoma, Neoadjuvant chemoradiotherapy, Response, Residual disease,
Accuracy, Sensitivity, Esophagectomy, Organ-sparing, Active surveillance
Background
Rationale
Esophageal cancer is the seventh most common can-
cer and the sixth most common cause of cancer-
related death worldwide. Highest incidence rates are
found in Asia, with over 90% of patients having squa-
mous cell carcinoma [1]. Of all patients with esopha-
geal cancer worldwide, roughly half live in China.
Almost half of the patients present with locally ad-
vanced disease and can be curatively treated with
neoadjuvant chemoradiotherapy (nCRT) followed by
surgery [2]. The CROSS trial showed that after nCRT
consisting of carboplatin and paclitaxel with concur-
rent 41.4 Gy radiotherapy, 23% of patients with
adenocarcinoma (AC) and 49% of patients with squa-
mous cell carcinoma (SCC) have a pathologically
complete response (pCR) in the resection specimen
[3, 4]. For these patients surgical resection might not
be necessary. Hence, an active surveillance strategy
has been proposed in which patients will undergo fre-
quent clinical response evaluations instead of standard
esophagectomy [5].
Active surveillance is currently being investigated in
two European clinical trials, i.e. the Dutch SANO trial
and the French ESOSTRATE trial, including patients
with both AC and SCC [6, 7]. Since the highest rate of
pCR after nCRT is achieved in patients with SCC, an ac-
tive surveillance strategy is highly relevant for Asian pa-
tients as well. This provides a rationale for a clinical trial
comparing active surveillance with standard esophagec-
tomy in patients with SCC showing a clinically complete
response after nCRT (Surgery If Needed for
Oesophageal cancer (SINO) trial). However, to justify
omitting a potentially curative surgical resection patients
with residual disease should be accurately identified. The
preSANO trial showed that a combination of fluoro-
deoxyglucose (18F-FDG) positron emission tomography
plus computed tomography (PET-CT), esophagogastro-
duodenoscopy (EGD) with bite-on-bite biopsies and
endoscopic ultrasonography (EUS) with fine-needle as-
piration (FNA) can identify substantial residual disease
(> 10% vital tumor cells, tumor regression grade (TRG)
3–4) with a sensitivity of 90% [8].
Since the majority of patients (78%) included in the
preSANO trial had adenocarcinoma and only 21% had
squamous cell carcinoma, it remains unclear whether re-
sidual squamous cell carcinoma after nCRT can be ac-
curately identified.
Aim
The aim of the present study is to assess the accuracy of
response evaluations according to the preSANO trial
outcome after nCRT according to the CROSS regimen
in patients with esophageal squamous cell carcinoma.
Methods
Study design and recruitment
The preSINO trial is a prospective, multicenter, diagnos-
tic cohort study. The study will be conducted in four
high-volume Asian hospitals, i.e. Shanghai Chest Hos-
pital (coordinating center), Taiwan Chang Gung Me-
morial Hospital, Tianjin Medical University Cancer
Center and Queen Mary Hospital of Hong Kong. The
study is planned to be initiated in August, 2019, and re-
sults are expected in August, 2022. The trial has been
registered at ClinicalTrials.gov as NCT03937362.
Eligibility criteria
Esophageal cancer patients who are planned to undergo
nCRT according to the CROSS regimen and who will
undergo surgical resection will be recruited for this
study. Patients will be considered eligible according to
the following criteria.
Inclusion criteria are:
1) Histologically confirmed esophageal squamous cell
carcinoma;
2) Tumor located in the chest;
3) Clinical stage cT1N1–2M0, cT2–4aN0-2M0,
according to the 8th Edition of the AJCC TNM
classification for Esophageal Cancer, where regional
lymph nodes with a diameter ≥ 10 mm and lymph
nodes around the left and right recurrent laryngeal
nerve with a diameter ≥ 6 mm on CT as well as
lymph nodes with a focal FDG signal above the
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adjacent esophageal background uptake are
considered positive;
4) Age > 20 at the date of informed consent;
5) Eastern Cooperative Oncology Group (ECOG)
Performance Status of two or less;
6) Considered fit to undergo nCRT followed by
surgical resection;
7) Expected survival time more than 3 months;
8) Written informed consent by the patient.
Exclusion criteria are:
1) Patient with a second primary tumor;
2) Previous major surgery in the chest or upper
abdomen;
3) Tumor not 18F-FDG-avid at baseline PET-CT;
4) Suspected positive lymph nodes that cannot be
covered by an uninterrupted radiation field that also
includes the primary tumor area;
5) Primary (early) lesion already removed by EMR/
ESD;
6) Previous history of chemotherapy and/or radiation
therapy;
7) Cervical esophageal cancer.
Study process (Fig. 1 and Table 1)
Baseline examination and inclusion
At baseline, patients will undergo an esophagogastroduode-
noscopy (EGD) with conventional tumor biopsy, endo-
scopic ultrasonography (EUS) in case of a traversable
tumor, external ultrasound of the neck, high resolution CT
of the neck, chest, abdomen and pelvis and whole-body
PET-CT to stage the tumor and to exclude distant dissem-
ination (Table 1). Preferably, photographs will be taken dur-
ing EGD for future reference. Cytology or histology must
be obtained from any suspected lymph nodes outside the
planned radiation field. Moreover, quality-of-life question-
naires will be obtained. Written informed consent for study
participation will be obtained from eligible patients after
baseline diagnosis and staging (Table 1).
Neoadjuvant chemoradiotherapy
All patients will receive nCRT according to the CROSS
regimen which consists of five weekly cycles of carbopla-
tin intravenously (iv) at an area under the curve (AUC)
of 2 mg/ml/min and paclitaxel iv at a dose of 50 mg/m2
on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy ex-
ternal beam radiotherapy given in 23 fractions of 1.8 Gy,
5 fractions per week, starting at the day of the first cycle
of chemotherapy [4].
CRE-1
Patients will undergo a first clinical response evaluation
(CRE-1) four to 6 weeks after completion of nCRT,
consisting of EGD with at least four bite-on-bite biopsies
(Fig. 2; Table 1). In every patient bite-on-bite biopsies
will be taken within the area of the primary tumor.
When performing bite-on-bite biopsies, a second biopsy
is taken at the exact location of the first biopsy. In total
at least four but preferably more bite-on-bite biopsies (≥
8 biopsies) have to be collected. In case suspected le-
sions are present, bite-on-bite biopsies should also be
taken of these lesions. If an ulcer is present, bite-on-bite
biopsies should be taken at the border where normal
mucosa meets ulcerative tissue. Photographs and/or a
video will be taken for future reference.
In case of histological evidence of locoregional disease
as well as in case of endoscopic non-traversable stenosis,
CRE-1 will be considered positive and the patient will be
identified as incomplete responder. These patients will
receive an additional PET-CT scan to exclude distant
metastases and will undergo subsequent esophagectomy.
Fig. 1 Flow chart of the preSINO trial. nCRT: neoadjuvant
chemoradiotherapy; CRE-1: first clinical response evaluation, four to
six weeks after completion of nCRT; CRE-2: second clinical response
evaluation, 10–12 weeks after completion of nCRT
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At this moment a CT scan could also suffice, because in
fact patients with a positive CRE-1 will drop out of the
trial. Patients with distant metastases will receive pallia-
tive care according to local protocol (Fig. 1). For patients
without histological evidence of residual tumor, surgery
will be postponed for another 6 weeks until the second
clinical response evaluation (CRE-2) 10–12 weeks after
completion of nCRT.
CRE-2
CRE-2 will be performed 10–12 weeks after completion
of nCRT (Fig. 1). At this stage, patients without histo-
logical evidence of residual tumor at CRE-1 will undergo
PET-CT scan, followed by EGD with bite-on-bite biop-
sies, and EUS with FNA of suspected lymph nodes
(Table 1). PET-CT scans will be made prior to endo-
scopic response evaluations to allow for histological con-
firmation of PET positive intramural lesions and
cytological confirmation of PET positive lymph nodes. A
detailed PET-CT protocol has been written which will
be used by all participating centers. In brief, all PET-CT
scans will be made at 60 ± 5min after injection of 2.96
MBq/kg 18F-FDG and will be performed according to
the EANM guidelines version 2.0 [10]. Low-dose CT
scans will be performed only for attenuation correction
and anatomical correlation of PET images. Patients in-
cluded in this study must have their CRE-2 PET-CT
scans done on the same or identical type of scanner,
under strictly the same conditions as their baseline PET-
CT scan. PET-CT scans will be analyzed qualitatively.
Lesions will be considered positive if any 18F-FDG up-
take in the lesion is above the adjacent esophageal back-
ground uptake [11]. At least 4 bite-on-bite biopsies will
be taken in the same way as during CRE-1. Subse-
quently, the entire esophagus will be assessed with EUS
for presence of suspected lymph nodes. The two (or if
possible three) most suspected lymph nodes will be sam-
pled with FNA. EUS criteria to define a lymph node as
suspected are lymph nodes that are round, hypoechoic
and larger than 5mm. However, based on experience of
Table 1 Study process
Parameter Baseline nCRT CRE-1 CRE-2 Surgery Follow-up
History, physical examination Yes Yes Yes Yes Yes Yes
ECOG Performance Status Yes Yes
Hematologya Yes Yes
Biochemistryb Yes Yes
Toxicity (CTCAE v5) Yesc
ECG Yes Ind.
Pulmonary function test Yes Ind.
Bronchoscopy Ind.d Ind.d
High resolution CT Yes Ind.e
External ultrasound of the neck Yes
Written informed consent Yes
EGD with ≥4 bite-on-bite biopsiesf Yesf Yes Yes
EUS with FNAg Ind. Yes
PET-CT Yes Ind.e Yes Yesh
QoL questionnairesi Yes Yes Yesi
nCRT neoadjuvant chemoradiotherapy, CRE-1 first clinical response evaluation, four to six weeks after completion of nCRT, CRE-2 second clinical response
evaluation, 10–12 weeks after completion of nCRT, Yes test will be performed, Ind test will be performed only on indication, ECOG Eastern Cooperative Oncology
Group, CTCAE v5 Common Terminology Criteria for Adverse Events version 5, ECG Electrocardiography, CT computed tomography, EGD
esophagogastroduodenoscopy, EUS endoscopic ultrasonography, FNA fine-needle aspiration, PET-CT positron emission tomography with computed tomography,
QoL quality of life
a Hematology: complete blood count and differential blood count;
b Biochemistry: serum protein, albumin, sodium, potassium, chloride magnesium, serum creatinine, eGFR, bilirubin, alkaline phosphatase, AST, and pregnancy test
if indicated;
c Toxicity according to the CTCAE v5 will be assessed after each cycle of chemotherapy;
d Bronchoscopy: in case of suspected tracheobronchial invasion based on other diagnostics;
e In case of histological evidence of locoregional residual disease at CRE, a whole body PET-CT scan or CT scan will be made to exclude distant metastases;
f Only during EGD at baseline it suffices if regular biopsies are taken instead of bite-on-bite biopsies;
g FNA will be performed of all suspected lymph nodes based on prior PET-CT and based on assessment during EUS;
h Follow-up PET-CT scans will be made at 16 and 30 months after completion of nCRT in patients who show a clinically complete response after CRE-2 to allow for
comparison of distant dissemination rate in the future SINO trial;
i QoL questionnaires EQ-5D, QLQ-C30, QLC-OG25 and Cancer Worry Scale will be taken at baseline, between CRE-2 and surgery. In patients who show a clinically
complete response after CRE-2 and undergo immediate surgery questionnaires will also be taken at 6, 9, 12, 16, 20 and 24months after completion of nCRT to
allow for comparison in the future SINO trial
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the preSANO and SANO trials it is known that about
50% of positive nodes after nCRT do not meet these
endosonographic criteria. Therefore, in case of any
doubt FNA should be performed and preferably lymph
nodes are sampled even in case of low suspicion. Re-
sponse evaluations are not for nodal staging only but for
detection of any residual tumor regardless of the origin
of the tumor cells. Contamination by malignant cells
from the primary tumor will thus have the same clinical
consequence as malignant cells from a positive lymph
node. Therefore, FNA will also be performed if lymph
nodes are located behind the (original) primary tumor.
Photographs and/or a video will be taken for future
reference.
Patients with distant metastases detected during CRE-
2 will drop out of the study and receive palliative care
(Fig. 1). Patients without distant metastases and without
histological evidence of locoregional residual disease will
be identified as clinically complete responders. In case of
histological evidence of locoregional disease as well as in
case of endoscopic non-traversable stenosis, CRE-2 will
be considered positive and patients will be identified as
incomplete responders. CRE-2 will not be considered
positive if PET-CT suggests locoregional disease in the
absence of histological confirmation. Both clinically
complete and incomplete responders will undergo an
esophagectomy shortly after CRE-2. If for any reason
(e.g. poor general condition after nCRT) esophagectomy
is postponed for more than 4 weeks after CRE-2, another
CRE (CRE-2b) will be performed just prior to the
planned operation.
Surgery
All patients without distant dissemination will undergo
an open, hybrid or minimally invasive transthoracic
esophagectomy (McKeown or Ivor Lewis) with at least
two-field (chest and abdomen) lymphadenectomy. Selec-
tion of surgical technique will depend on patient and
tumor characteristics as well as local expertise and
preference.
Pathology
All biopsies will be evaluated by expert gastrointestinal
pathologists. First, regular HE slides will be analyzed for
vital tumor cells. If no malignancy can be identified, two
or three additional sections will be performed and ana-
lyzed. In case the presence of vital tumor cells is still un-
certain, extra diastase-periodic acid Schiff (dPAS) and
Fig. 2 Bite-on-bite biopsy. During bite-on-bite biopsy [1–4] an extra biopsy [3, 4] is taken at the location of the previous biopsy [1, 2]. This
procedure hypothetically increases the chance of detecting residual submucosal disease compared to conventional biopsies [1, 2]. (from:
Noordman BJ, Wijnhoven BPL, Lagarde SM, Biermann K, van der Gaast A, Spaander MCW, et al. Active surveillance in clinically complete
responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Dis Esophagus. 2017;30 [9]:1–8. With permission of Oxford
University Press)
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(pan) keratin staining will be performed. Analysis of
three additional sections and dPAS and keratin staining
will always be performed if signet-ring cell carcinoma or
a poorly cohesive carcinoma with mucin production was
originally diagnosed. In case the pathological examin-
ation of the biopsy specimen concludes an uncertain
outcome or high-grade/severe dysplasia, a second expert
gastrointestinal pathologists will revise the specimen. In
case of a discordant outcome, the specimens will be
reviewed by a third independent expert pathologist. A
final diagnosis will be made only if at least two patholo-
gists agree. In case the consensus diagnosis concludes
high-grade/severe dysplasia, the CRE will be considered
positive. In case the outcome remains uncertain, the bi-
opsies will also be considered positive for patients’
safety.
The resection specimen will be evaluated by two inde-
pendent pathologists. Pathological examination will be
performed according to standard protocol. Pathology re-
ports should contain at least histological type, tumor
size, proximal and distal resection margins, circumferen-
tial resection margin, invasion depth, grade of differenti-
ation, lymphovascular invasion, number of resected
nodes, number of resected positive nodes, tumor regres-
sion grade (TRG), ypTNM stage and prepTNM stage
[12]. Microscopically radical resection (R0) will be de-
fined as a tumor-free resection margin (margin > 1 mm
not required). TRG will be categorized into four grades
according to Chirieac: [9] TRG1: no residual carcinoma,
characterized by microscopic evidence of radiation in-
duced tissue injury, regenerative changes, and fibrosis
extending through the layers of the esophageal wall.
There is no histologically identifiable residual carcinoma.
TRG2: 1–10% residual carcinoma, characterized by rare
individual carcinoma cells present in fibrotic tissue at
the primary site. TRG3: 11–50% residual carcinoma,
characterized by microscopic foci of carcinoma cells
present at the primary site. TRG4: greater than 50% re-
sidual carcinoma, characterized by substantial carcinoma
remaining at the primary site. Pathological staging will
be performed according to the 8th Edition of the AJCC
TNM Classification for Esophageal Cancer [13]. The
pathologist should try to identify at least 15 lymph nodes
according to the National Comprehensive Cancer Net-
work (NCCN) guidelines. However, the preferred aver-
age number of dissected and identified lymph nodes is
more than 23 [14].
Follow-up
Patients having cCR in the preSINO trial can be in-
cluded into the control arm (standard esophagectomy)
of the planned future SINO trial as well. Since quality of
life will be an important endpoint in the SINO trial,
quality of life will be measured in patients included in
the preSINO trial with EQ-5D, QLQ-C30, QLC-OG25
and Cancer Worry Scale questionnaires (Table 1) [15–
18]. These questionnaires will be taken in all patients at
baseline (pre-treatment) as well as between CRE-2 and
surgery (3 months after completion of nCRT). In pa-
tients who show cCR after CRE-2 and undergo immedi-
ate surgical resection, the questionnaires will be taken at
another six time points, i.e. 6, 9, 12, 16, 20 and 24
months after completion of nCRT.
A second important endpoint for the planned future
SINO trial is the distant dissemination rate. In the ex-
perimental arm (active surveillance) of the SINO trial,
PET-CTs will be frequently made during response evalu-
ations. To compare the distant dissemination rate be-
tween both study arms, patients included in the control
arm should undergo follow-up PET-CT scans as well, al-
beit less frequently. PET-CT scans will be made at 16
and 30months after completion of nCRT in patients
who show cCR after CRE-2 (Table 1). These patients
must have their follow-up PET-CT scans done on the
same or identical type of scanner, under strictly the
same conditions as their baseline and CRE-2 PET-CT
scan.
Study endpoints
In line with the preSANO trial, it is hypothesized that
for an active surveillance strategy in a future SINO trial
TRG2 residual tumors (1–10% residual carcinoma) can
be safely missed since the tumor will likely be detected
in a resectable stage during a subsequent response evalu-
ation. However, residual nodal disease without residual
disease at the primary tumor site (ypT0N+) after nCRT
tends to occur more frequently in patients with SCC
than in patients with AC. Based on a large Dutch
CROSS cohort comprising participants of the CROSS-I
and CROSS-II trials, post-CROSS cohort and the pre-
SANO trial, 7% of patients with SCC and 3% of patients
with AC had ypT0N+ stage after nCRT according to
CROSS. Therefore, the primary endpoint of the pre-
SINO trial is the accuracy of both CRE-1 and CRE-2
combined for detecting TRG3–4 residual tumor (> 10%
residual carcinoma) or TRG1–2 (≤10% residual carcin-
oma) with ypN+ (any residual nodal disease) in the sur-
gical resection specimen. Secondary endpoints are the
accuracy of both CRE-1 and CRE-2 combined for detect-
ing pathologically non-complete response in both the
primary tumor and regional lymph nodes (TRG2–4 or
ypN+) as well as the association between the outcome of
each single diagnostic modality and the pathological re-
sponse (TRG, ypN) in the surgical resection specimen.
Patient safety
Stop rules have been defined to guarantee maximum pa-
tient safety during the trial. A data safety and monitoring
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board (DSMB) will be established that will test the stop
rules repeatedly. In case a stop rule is reached, the trial
will be stopped immediately in all participating centers.
Patients that have already been included and that have
finished neoadjuvant treatment will not undergo any fur-
ther research-related tests. These patients will be sched-
uled for surgical resection with minimal additional delay.
Patients that are still receiving nCRT will continue their
treatment and will undergo subsequent surgical resec-
tion according to standard protocol for esophageal
cancer.
The following safety parameters will be closely
monitored:
– The number of clinically relevant iatrogenic
perforations resulting in an abscess, empyema and/
or sepsis,
– The number of other treatment related
complications (e.g. bleeding, aspiration, myocardial
infarction) that lead to cancellation or
postponement of surgery for at least 14 days.
– the number of patients that undergo a




In the preSANO trial, missing 10% of the patients with
TRG3–4 residual tumor at the site of the primary tumor
(false-negative rate of 10%) was considered acceptable in
order to start an RCT comparing active surveillance with
standard resection (SANO trial) [19]. In the preSINO
trial, regional lymph nodes will also be evaluated. The
acceptable false-negative rate will be increased with 2%
because survival of patients with ypN+ is worse than pa-
tients who have ypN0, regardless of whether they are
missed during clinical response evaluations or not. This
increase of 2% will also prevent an exceedingly large
sample size. Hence, missing 12% of the patients with
TRG3–4 or TRG1–2 with ypN+ residual disease (false-
negative rate of 12%) will be considered acceptable.
In the preSINO trial only patients with SCC will be in-
cluded, while in the preSANO trial three quarters of pa-
tients had AC. Accounting for the better response to
CROSS of patients with SCC than patients with AC (and
thus a different distribution of TRG and ypN stages), a
false-negative rate of 12% in a Dutch cohort with a ma-
jority of patients with AC corresponds to an allowed
false-negative rate of 19.5% in a cohort of only patients
with SCC.
With a power of 80%, a significance of 5% and an ex-
pected sensitivity of 89% for detecting TRG3–4 or
TRG1–2 with ypN+ residual disease (from the preSANO
trial), sample size calculations resulted in a required
sample size of 133 patients with TRG3–4 or TRG1–2
with ypN+ residual disease to show that the sensitivity
of the CREs is at least 80.5%.
Since 34% of patients with SCC showed TRG3–4 or
TRG1–2 with ypN+ residual disease after nCRT accord-
ing to CROSS, this results in a total sample size (TRG1–
4 and any ypN stage) of 391 patients. To allow for a 15%
drop-out (e.g. patients who do not undergo surgery due
to metastases or due to patients’ choice to undergo an
active surveillance strategy, 460 patients will be in-
cluded. After interim analyses (performed at 50, 100,
200 inclusions) the distribution of TRG stages will be
checked. According to the rate of TRG3–4 and TRG1–2
with ypN+ in these interim analyses, a new total sample
size will be recalculated.
Data analysis
For primary data analysis the results of PET-CT, endo-
scopic bite-on-bite biopsies and EUS with FNA during
CRE-1 and CRE-2 will be combined into one overall
conclusion (cCR or clinically non-complete response).
The number of true-positives, false-positives, true-
negatives and false-negatives will be assessed. Based on
these values, sensitivity, specificity, negative predictive
value and positive predictive value will be calculated for
CREs predicting TRG3–4 or TRG1–2 with ypN+ re-
sidual disease. Similarly, these values will be calculated
for CREs predicting TRG2–4 or ypN+ residual disease
(any locoregional residual disease). For secondary ana-
lysis, multiple imputation will be used for missing TRG
scores of patients who have cCR after CRE-2 and who
underwent subsequent active surveillance instead of sur-
gical resection. Moreover, outcome of the single diag-
nostic modalities will be correlated with pathological
response using χ2 test. An interim analysis will be per-
formed after 50, 100 and 200 patients have been in-
cluded. This analysis will be performed similarly to the
primary data analysis. The number of true-positives,
false-positives, true-negatives, false-negatives and the
distribution of TRG stages together with the results of
the assessment of both stop rules will be reported to the
DSMB and IRB. If during these interim analyses the pro-
portion of TRG3–4 and TRG1–2 with ypN+ patients is
higher or lower than expected, the sample size will be
recalculated to decrease or increase the number of pa-
tients that have to be included in the trial accordingly.
Discussion
This preSINO study is a diagnostic trial, investigating
the combination of diagnostic modalities that has been
tested previously in the preSANO trial. It will provide
evidence concerning the optimal diagnostic strategy for
detecting residual locoregional disease after nCRT and,
if successful, will be applied in a future SINO trial
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comparing active surveillance with standard esophagec-
tomy in patients with esophageal SCC.
Esophageal SCC is a major public health issue for Cen-
tral, East- and South-East Asian countries. Highest inci-
dences are found in these areas with rates up to 13.6 per
100,000 in men and 4.3 in women (compared to a global
average of 7.7 in men and 2.8 in women). In China,
esophageal cancer is the fourth most common cancer,
making it a major (financial) burden for Chinese na-
tional healthcare [20]. Hence, a potential reduction in
the number of esophagectomies might not only have a
positive impact on patients’ wellbeing, but also on the
burden of esophageal cancer on Chinese healthcare
systems.
Active surveillance after nCRT has been proposed for
esophageal cancer since high pCR rates are being
achieved by current nCRT regimens [5]. The Dutch
CROSS trial showed that 5-year overall survival signifi-
cantly increased from 33 to 47% by applying nCRT con-
sisting of carboplatin and paclitaxel with concurrent
41.4 Gy radiotherapy prior to surgical resection [3]. Fol-
lowing this nCRT regimen, 49% of patients with SCC
and 23% of patients with AC had pCR. However, only a
small part of the included patients had SCC (23%) [4].
The Chinese NEOCRTEC 5010 trial showed that 3-year
overall survival increased from 58.9 to 69.1% by giving
nCRT consisting of vinorelbine and cisplatin with con-
current 40.0 Gy radiotherapy prior to surgical resection
[21]. In this Chinese trial including only esophageal
SCC, 43.2% of patients achieved pCR. Although pCR
rates in patients with SCC are comparable between both
regimens (49% vs. 43.2%), the CROSS regimen has been
proposed as optimal nCRT regimen for the preSINO
trial and future SINO trial. The major issue with nCRT
according to the NEOCRTEC 5010 regimen is the rela-
tively high toxicity rate. In the CROSS trial fewer grade
3–4 adverse hematological events (7.6%) occurred com-
pared to 54.3% in the NEOCRTEC 5010 trial [4, 21].
The significance of the current preSINO study is that
after nCRT according to CROSS, pCR rates tend to be
higher in patients with SCC compared to patients with
AC (49% vs 23%) [4]. In these patients surgical resection
can potentially be postponed or even omitted. Hence, al-
most half of patients with SCC could benefit from an ac-
tive surveillance strategy. However, the results of the
preSANO trial cannot be simply extrapolated to the
planned SINO trial since the preSANO trial included
only 21 patients (17%) with SCC who underwent bite-
on-bite biopsies and 43 patients with SCC overall (21%)
[8].
Compared to the preSANO trial, the current study dif-
fers on several aspects. In the preSANO and subsequent
SANO trial, operable patients who underwent or who
were planned to undergo nCRT according to the CROSS
regimen are/were considered eligible [7, 8]. However,
patients with AJCC cN3 disease have a high risk of an
incomplete locoregional response and a low chance of
remaining tumor-free during follow-up in the planned
future SINO trial. Also, these patients often have sus-
pected lymph nodes outside the maximum tolerated ra-
diation field and can therefore not receive CROSS
chemoradiotherapy. Since inclusion of cN3 patients in
the preSINO and SINO trial could reduce the propor-
tion of cCR and pCR, patients with cN3 disease will not
be included in the preSINO trial. Moreover, in the pre-
SANO trial PET-CT was used to identify distant metas-
tases at baseline and preoperatively. In the preSINO
trial, patients who have a positive CRE-I (i.e. histologi-
cally proven locoregional residual disease or a non-
traversable tumor) are also allowed to receive a high-
dose CT scan instead of a PET-CT scan in order to
identify distant metastases. Although high-dose CT scan
is inferior to PET-CT scan in detecting distant metasta-
ses for esophageal cancer [22], Chinese insurance does
not yet cover a preoperative PET-CT scan. However,
both in the present preSINO trial and in the planned
subsequent SINO trial the group of patients with a posi-
tive CRE-I (and CRE-II) will be excluded. Therefore,
performing a high dose CT scan instead of PET-CT scan
after a positive CRE-I will not affect the preSINO and
SINO trials.
Furthermore, in the preSANO trial the reference
standard that has been used for calculating the accuracy
of the CREs was TRG in the resection specimen [8].
This grading system evaluates the response of the pri-
mary tumor site to neoadjuvant treatment only. How-
ever, the modalities used in the CREs also evaluate
residual nodal disease. After nCRT, 4–9% of patients
with SCC have a pathologically complete response at the
primary tumor site with residual disease in the regional
lymph nodes (ypT0N+), compared to 3–5% of patients
with AC [23–25]. For these patients, higher ypN stage is
correlated with worse overall survival [25]. However,
these studies did not clearly specify the nCRT regimens
that patients received. Moreover, the majority of patients
probably did not receive nCRT according to the CROSS
regimen since they were included before the results of
the CROSS trial were published [23, 24]. Accordingly,
data of a large Dutch CROSS cohort comprising patients
that were included in the CROSS-I and CROSS-II trials,
post-CROSS cohort and the preSANO trial were ana-
lyzed. In this large CROSS cohort, 8 of 122 patients with
SCC (7%) and 11 of 415 patients with AC (3%) who
underwent nCRT followed by a surgical resection had
ypT0N+ stage. The percentage of patients with ypT0
who had ypN+ was comparable between SCC and AC
(14% vs. 13%, resp.), suggesting that the higher rate of
ypT0N+ patients is mainly caused by the better response
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of SCC to nCRT according to CROSS. In an active sur-
veillance strategy that focusses on the primary tumor
site only, patients who have ypT0N+ stage run a high
risk of developing distant metastases. Therefore, in con-
trast to the preSANO trial, the preSINO trial will aim to
identify patients with residual disease at the primary
tumor site as well as in regional lymph nodes.
Similar to the preSANO trial, this trial will use bite-
on-bite biopsies during endoscopic response evaluation.
After nCRT for esophageal cancer, residual disease is
found in deeper layers than the mucosa without residue
in the mucosa itself in 24–40% of patients [26, 27]. In
case of bite-on-bite biopsies, the second biopsy is taken
at the exact same location as the first biopsy (Fig. 2). It
has been suggested that this biopsy technique has the
potential to reach into the submucosa, thereby increas-
ing the rate of detecting residual tumor. The preSANO
trial was started with regular endoscopic biopsies. How-
ever, sensitivity for detecting TRG3–4 residual tumor
improved from 69 to 90% after the protocol had been
changed from regular biopsies to bite-on-bite biopsies.
Moreover, the preSANO trial demonstrated that per-
forming FNA of suspected lymph nodes substantially
improved detection of residual disease. It was shown
that 29% of residual disease detected during CRE-2 alone
was based on results of FNA only. Based on bite-on-bite
biopsies only, sensitivity of both CRE-1 and CRE-2 com-
bined for detecting TRG3–4 residual tumor was 83%.
With the addition of FNA, this increased to 90% [8].
As demonstrated by the preSANO trial, the additional
value of qualitative and quantitative PET-CT analysis in
detecting early residual locoregional disease (up to 12
weeks after completion of nCRT) remains disputable.
Qualitative PET-CT analysis alone yielded a reasonable
sensitivity of 85% for detecting TRG3–4 residual tumor
and a sensitivity of 80% for detecting TRG2–4 residual
tumor. However, corresponding specificity was only
37%, caused by a high number of false-positives [8, 11].
After nCRT, radiation-induced esophagitis apparently
increases 18F-FDG uptake throughout the irradiated
esophagus including the primary tumor site, thereby in-
creasing false-positive response evaluations. PET-CT de-
tected novel distant metastases (i.e. not detected at
baseline) in 9% of patients during CRE-2, saving them
from unnecessary surgical resection [8, 11]. For this
reason, in the current study PET-CT will only be
used to detect distant metastases and will not be used
for evaluating the primary tumor site. In the planned
future SINO trial investigating an actual active sur-
veillance strategy, PET-CT might become valuable as
esophagitis will probably diminish over time, allowing
detection of disease recurrence by qualitative and
semi-quantitative analysis of small increments in 18F-
FDG uptake.
Moreover, PET-CT will be used in follow-up to com-
pare the distant dissemination rate between both arms
of the future SINO trial. For patients undergoing active
surveillance in the future SINO trial there is a hypothet-
ical risk of increased distant dissemination since residual
vital tumor might be missed during response evalua-
tions. Current assumption holds that this process of
spreading and seeding of tumor cells from the primary
lesion is an early event. Hence, distant dissemination
might have already happened at the time of diagnosis or
during locoregional treatment [28]. This assumption is
reflected by the substantial number of patients who de-
velop hematogenous metastases after nCRT plus esopha-
gectomy within 2 years after surgery [3, 4]. For this
reason, PET-CTs will be performed until 2 years after
surgical resection in the control arm (immediate sur-
gery) of the planned future SINO trial. Since patients
with a clinically complete response in the preSINO trial
can be included in this arm of the SINO trial, these pa-
tients will also undergo follow-up PET-CT scans.
Although the preSANO trial showed that the combin-
ation of endoscopic bite-on-bite biopsies, EUS, and PET-
CT was most accurate for detecting residual disease after
nCRT, other measurements and modalities for response
evaluation have been considered. To our knowledge,
however, no other single modality or set of modalities
has yet acquired an accuracy that equals the set from
the preSANO trial. Moreover, because PET-CT, endo-
scopic biopsies and EUS are widely used for pretreat-
ment clinical staging, physicians have experience with
these techniques and they are available in most Chinese
centers. One of the other measurements considered for
the preSINO trial was the maximum tumor thickness on
EUS as proposed by Jost et al. [29] In a cohort of 40 pa-
tients they found a sensitivity of 86% and specificity of
64% for detecting TRG 2–4 residual tumor. Based on
these results, the preSANO trial investigated this
method in 123 patients. In this larger cohort, a sensitiv-
ity of only 59% and specificity of 58% was found. Since
these measurements did not add to the accuracy of the
set of diagnostic modalities in the preSANO trial, it was
decided that they are not included in the preSINO trial
protocol [8]. MRI is another promising modality, show-
ing sensitivities up to 97% for detecting residual tumor
after nCRT [30, 31]. However, studies that find these
high sensitivities all have poor corresponding specific-
ities of at most 58%. In a future SINO trial, this oversta-
ging of patients with a complete response to nCRT
would result in unnecessary surgery. Blood-based bio-
markers, including circulating tumor DNA, could also
become useful for less invasive detection of residual dis-
ease. Methods have improved over the last few years, es-
pecially for predicting distant recurrences [32, 33]. To
date, however, no biomarker has been identified that can
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accurately discriminate patients with incomplete locore-
gional response from patients with complete locoregio-
nal response.
If the preSINO trial shows that PET-CT, endoscopic
bite-on-bite biopsies and EUS with FNA can detect
TRG3–4 residual tumor in patients with esophageal
SCC with a sensitivity of at least 81.5%, this combination
of diagnostic tests will be used in a subsequent prospect-
ive trial comparing active surveillance with standard
esophagectomy in patients with SCC and a clinically
complete response after nCRT (SINO trial). Similar to
the preSANO and SANO trials, it will be possible to in-
clude all patients of the preSINO trial having cCR into
the control arm of the future SINO trial [7]. Of patients
with SCC receiving nCRT according to CROSS, almost
50% achieve pCR and more than 50% is expected to have
cCR. Consequently, the number of study subjects needed
for the SINO trial can be substantially decreased com-
pared to the SANO trial. Most probably, all patients
needed for the control arm of the SINO trial will be de-
rived from the preSINO trial.
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